Numeric Investors’s Titan Pharmaceuticals TTNP Stock Holding History

Numeric Investors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3	Closed	-$48K	–	1156
2016 Q4	$48K	Buy	+3	New	+$50.5K	﹤0.01%	1012

Other funds holding TTNP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

STRS Ohio Columbus, Ohio $25.2B AUM 30.31% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Numeric Investors's TTNP Position: Q1 2017 in Review

Numeric Investors sold out of Titan Pharmaceuticals (TTNP) in Q1 2017, closing a stake of 3 shares — an estimated $48K sold.

Numeric Investors first reported a position in TTNP in Q4 2016 and held it in 1 quarter. The position peaked at $48K in Q4 2016. 40 funds tracked by Wall St. Rank hold TTNP as of Q1 2017.

Numeric Investors reported no remaining Titan Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Numeric Investors sold 3 Titan Pharmaceuticals shares in Q1 2017, an estimated $48K.
Numeric Investors first reported a position in Titan Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Numeric Investors's Titan Pharmaceuticals position peaked at $48K in Q4 2016.
40 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q1 2017.

Based on Numeric Investors's 13F filing for Q1 2017, filed 15 May 2017.